Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab vs Docetaxel in Previously Treated NSCLC (IMpower210)
NCT02813785Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2016
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Jul 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02813785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02813785.